{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Neurogene Inc."},"Symbol":{"label":"Symbol","value":"NGNE"},"Address":{"label":"Address","value":"535 W 24TH ST,5TH FLOOR, NEW YORK, New York, 10011, United States"},"Phone":{"label":"Phone","value":"+1 (877) 237-5020"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York."},"CompanyUrl":{"label":"Company Url","value":"https://www.neurogene.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Arvind Sreedharan","title":"Senior Vice President-Business Operations"},{"name":"Julie Jordan","title":"Chief Medical Officer"},{"name":"Rachel L. McMinn","title":"Chairman & Chief Executive Officer"},{"name":"Ricardo Jimenez","title":"Senior Vice President-Technical Operations"},{"name":"Stuart Cobb","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}